Skip to content
Biodatica
Start free

NEONC TECHNOLOGIES HOLDINGS, INC.

CALABASAS, CA · also filed as None

OncologyPhase IIListed · NTHI

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

4d agoTrial registeredJul 16, 2026Source filing (opens the source filing in a new tab)

Momentum

93no change

Momentum 93 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

~2months

The model puts this company near the end of its last raise.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form D · $5.0M

    Jun 25, 2026

    NEONC TECHNOLOGIES HOLDINGS, INC. · private raise, self-reported by the issuer

    SEC EDGAR · 0001829126-26-006874 (opens the source filing in a new tab)

  2. Filing

    Form D · $11M

    Feb 9, 2026

    NEONC TECHNOLOGIES HOLDINGS, INC. · private raise, self-reported by the issuer

    SEC EDGAR · 0001979414-26-000001 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jan 1, 2026

    Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma · NOT_YET_RECRUITING · sponsor: Neonc Technologies, Inc. · A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

    ClinicalTrials.gov · NCT06357377 (opens the source filing in a new tab)

  4. Filing

    Form D · $1.0M

    Dec 18, 2025

    NEONC TECHNOLOGIES HOLDINGS, INC. · private raise, self-reported by the issuer

    SEC EDGAR · 0001979414-25-000006 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Nov 1, 2023

    Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma · RECRUITING · sponsor: Neonc Technologies, Inc. · Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    ClinicalTrials.gov · NCT06047379 (opens the source filing in a new tab)

  6. Trial

    PHASE1/PHASE2 registered

    Aug 1, 2017

    Glioblastoma Multiforme · ACTIVE_NOT_RECRUITING · sponsor: Neonc Technologies, Inc. · Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

    ClinicalTrials.gov · NCT02704858 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources